From a celebrity-spruiked success to a relic of diet culture. How a changing world of nutrition led to Weight Watchers' bankruptcy.

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

A clinical trial showed that Lilly's weight loss medicine is superior to a key competitor's product. Eli Lilly (NYSE: LLY) is ...

A number of patients, including at least three from Long Island, contend they suddenly lost their vision after taking the widely popular weight loss drugs Ozempic and Wegovy, according to a Long ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.

Novo Nordisk's (NVO) investors are worried its competition with Eli Lilly (LLY) is heating up and that the first-to-market GLP-1 leader is losing ground. Even with 72% of the global market share ...

The Therapeutic Goods Administration has received complaints of blindness and vision loss in one eye among users of Ozempic and Wegovy, who are reluctant to ditch the weight-loss drugs.

MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...